tbi

TBI-166, an orally active riminophenazine analogue, serves as an anti-tuberculosis agent and exhibits fewer adverse reactions compared to its lead compound, Clofazimine [1] [2] [3].

TBI-223 is an orally bioavailable oxazolidinone antibiotic with antimicrobial properties. It exhibits potent activity against Mycobacterium tuberculosis (Mtb)[1][2].

MTOB (α-keto-γ-Methylthiobutyric acid) is a substrate for c-terminal binding protein (CtBP) that interferes with the carcinogenic activity of CtBP in cell culture and mice. It also actively regulates TCF-4 signaling, leading to cancer stem cell (CSC) growth and self-renewal.

tBID is a selective homeodomain-interacting protein kinase 2 (HIPK2) inhibitor (IC50 of 0.33 µM)

Etbicyphat (Trimethylopropane phosphate), a potent competitive antagonist of GABA(A) receptors, binds to GABA(A)-benzodiazepine receptors and induces epileptiform activities in hippocampal CA1 neurons.

Astragaloside may protect against brain contusion and neuronal apoptosis after TBI by attenuating microglia activation in male rats. Astragalosides-induced apoptosis in NB4 cells may be associated with down-regulation of the expression of BCL-2 and NF-κB,

The P7C3 class of neuroprotective aminopropyl carbazoles has been shown to block neuronal cell death in models of neurodegeneration. We now show that P7C3 molecules additionally preserve axonal integrity after injury, before neuronal cell death occurs, in

RX 801077 (2 BFI free base), a selective imidazoline I2 receptor (I2R) agonist, exhibits a K i value of 70.1 nM, demonstrating anti-inflammatory and neuroprotective properties. This compound holds research potential for traumatic brain injury (TBI).

Candesartan (CV 11974) is an angiotensin II receptor blocker used widely in the therapy of hypertension and heart failure.

Astragaloside, one of the main active ingredients in Astragalus membranaceus.